Prideapplication/xmlftp://ftp.pride.ebi.ac.uk/pride/data/archive/2024/01/PXD047367/checksum.txtftp://ftp.pride.ebi.ac.uk/pride/data/archive/2024/01/PXD047367/Na7.rawftp://ftp.pride.ebi.ac.uk/pride/data/archive/2024/01/PXD047367/C-3.rawftp://ftp.pride.ebi.ac.uk/pride/data/archive/2024/01/PXD047367/C-2.rawftp://ftp.pride.ebi.ac.uk/pride/data/archive/2024/01/PXD047367/C-1.rawftp://ftp.pride.ebi.ac.uk/pride/data/archive/2024/01/PXD047367/Na8.rawftp://ftp.pride.ebi.ac.uk/pride/data/archive/2024/01/PXD047367/Na9.rawftp://ftp.pride.ebi.ac.uk/pride/data/archive/2024/01/PXD047367/txt.zipprimaryOK200w_angei@126.comWei WangData-dependent acquisitionMass SpectrometryTranscriptomics; proteomics; alkali burns; corneal neovascularization; mice; lcp1; csrp2; tgm2; tgfbiproteomicsTranscriptomicscorneal neovascularizationtgfbilcp1micecsrp2alkali burnstgm2https://www.ebi.ac.uk/pride/archive/projects/PXD047367CorneaProtein extraction from tissues was carried out using a cold radioimmunoprecipitation assay (RIPA) lysis buffer (Beyotime, China) supplemented with phenylmethane sulfonyl fluoride (Beyotime, China) on ice for 15 minutes. Subsequently, the lysis mixtures were centrifuged at 14,000 × g for 10 minutes at 4 °C. The resulting supernatants were then collected to determine the protein concentration using the bicinchoninic acid (BCA) protein assay kit (Beyotime, China). The proteins were stored at −80 °C until preparation for analysis. For assessing protein quality, 20 µg of protein from each sample was separated on SDS‒PAGE gels (at a continuous voltage of 200 V for 40 min) and then stained with Coomassie blue. Each sample, comprising 100 µg of proteins, was first reduced with 100 mM DTT for 5 minutes at 100 ℃ and then alkylated with 100 mM iodoacetamide for 30 minutes in the dark. Subsequently, the protein suspensions underwent digestion with 4 μg of trypsin (Promega) in 40 μL of 50 mM NH4HCO3 buffer overnight at 37 ℃, and the resulting peptides were collected as a filtrate. Finally, the peptide segment was desalted using a C18 column. The samples underwent chromatography using the Easy nLC system (Thermo Fisher Scientific, USA), followed by analysis with an Orbitrap Exploris 480 mass spectrometer (Thermo Fisher Scientific, USA). The peptides (2 μg) were loaded onto the C18 reverse-phase analytical column (Thermo Fisher Scientific, USA) in buffer A (0.1% formic acid), followed by separation with a linear gradient of buffer B (80% acetonitrile and 0.1% formic acid) at a flow rate of 300 nL/min. Mass spectrometry (MS) data was acquired using a data-dependent top10 method that dynamically chose the most abundant precursor ions from the survey scan (350–1200 m/z) for HCD fragmentation. MS1 scans were obtained with an AGC target of 300% and a maximum IT of 50 ms, acquired at a resolution of 120,000 at m/z 200. Operating in a data-dependent mode with a cycle time of 1.5 s, MS2 scans were obtained at a resolution of 15,000 at m/z 200, with an AGC target of 75%, a maximum IT of 35 ms, and an isolation width of 1.6 m/z. The normalized collision energy was set to 33%, and the dynamic exclusion for selected ions was set to 30 s.PrideThe MS raw files were analyzed using MaxQuant software (version 1.6.17.0) and searched against the database Uniprot_MusMusculus_17107_20220308_swissprot. Carbamidomethylation of cysteines was set as a fixed modification, while protein N-terminal acetylation and methionine oxidation were considered variable modifications for database searching. The global false discovery rate (FDR) cutoff for peptide and protein identification was set to 0.01. Protein abundance was calculated based on normalized spectral protein intensity (LFQ intensity). Proteins with a fold change > 2 or < 0.5 and a p-value < 0.05 were considered differentially expressed proteins (DEPs).ProteomicsWei WangDepartment of Ophthalmology, Shanghai Tenth People’s Hospital, School of Medicine, Tongji University, Shanghai 200072, China.PARTIALMus Musculus (mouse)w_angei@126.com38190126 Wang W, Deng M, Li M, Liu L, Zou J, Qian Y. Exploring Corneal Neovascularization: An Integrated Approach Using Transcriptomics and Proteomics in an Alkali Burn Mouse Model. Invest Ophthalmol Vis Sci. 2024 65(1):21 10.1167/iovs.65.1.21Department of Ophthalmology, Shanghai Tenth People’s Hospital, School of Medicine, Tongji University, Shanghai, ChinaChina<h4>Purpose</h4>Corneal neovascularization (CNV) impairs corneal transparency and visual acuity. The study aims to deepen our understanding of the molecules involved in CNV induced by alkali burns, facilitate a better grasp of CNV mechanisms, and uncover potential therapeutic targets.<h4>Methods</h4>Eighty-four mice were selected for establishing CNV models via alkali burns. On days 3, 7, and 14 after the burns, corneal observations and histological investigations were conducted. An integrated analysis of RNA sequencing (RNA-seq)-based transcriptomics and label-free quantitative proteomics was performed in both normal and burned corneas. Bioinformatics approaches, encompassing Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis, were applied to discern differentially expressed genes (DEGs) and crucial signaling pathways. Four potentially CNV-related genes were validated using quantitative real-time PCR (qRT-PCR) and Western blot.<h4>Results</h4>Significant CNV was observed on the seventh day. Forty-one genes were differentially expressed in neovascularized corneas, with 15 upregulated and 26 downregulated at both mRNA and protein levels. Bioinformatics analysis revealed that these DEGs participated in diverse biological processes, encompassing retinol and retinoic acid metabolism, neutrophil chemotaxis, and actin filament assembly, along with significant enrichment pathways like cytochrome P450, tyrosine, and phenylalanine metabolism. The upregulation of lymphocyte cytosolic protein 1 (LCP1) and cysteine and glycine-rich protein 2 (CSRP2) genes and the downregulation of transglutaminase 2 (TGM2) and transforming growth factor-beta-induced (TGFBI) genes were confirmed.<h4>Conclusions</h4>We analyzed gene expression differences in mouse corneas 7 days after alkali burns, finding 41 genes with altered expression. The exact role of these genes in CNV is not fully understood, but exploring angiogenesis-related molecules offers potential for CNV treatment or prevention.Exploring Corneal Neovascularization: An Integrated Approach Using Transcriptomics and Proteomics in an Alkali Burn Mouse Model.Wang Wei W, Deng Manli M, Li Min M, Liu Lin L, Zou Jun J, Qian Yiyong YMus musculus, Laboratory Mice., Alkalis, Corneal Angiogenesis, Peptidomics, Laboratory, Swiss, mice, Mus domesticus, Corneal Neovascularization, Angiogenesis, Alkali, mouse, Swiss Mouse, Corneal neovascularization NOS (disorder), House Mice, Swiss Mice, Unspecified corneal neovascularization (disorder), Neovascularization, House Mouse, Corneal neovascularization (disorder), domesticus, Corneal Neovascularizations, unspecified, House, Mus, Corneal, Corneal neovascularization, Burn, Mus musculus domesticus, Mouse, house mouse, corneal neovascularization, Neovascularizations, Mice, Laboratory Mouseprojections, Ribonucleic, para Tyrosine, Materials, LCD1, F14M4.21, DL3735W, F6G17_50, F14M4.22, MJB24.3, POLYPEPTIDE 7, FAMILY 77, MJB24.7, Corneal Neovascularization, T20B5_9, Cytochrome P 450 Monooxygenase, qRT-PCR, F4P12.1, F6G17_60, T11J7.16, T11J7.14, F3L17.70, 1, 3, 4, 6, lcd1, MOJ9.6, Non Polyadenylated, F6G17.50, T11J7_16, T11J7_14, molecules, kus, I, beta1tub, 2-amino-3-(4-hydroxyphenyl)propanoic acid, 3-(p-Hydroxyphenyl)alanine, CYP90A, F2P9_2, T, MDN11.4, procedures, DL3710C, Y, C14orf92, F6G17.60, F3L17_70, F6A4.110, e, F22H5.19, beta1Tub, F6G17_80, CYTOCHROME P450, CDGG1, F13O11.20, F6A4.120, Anchored Polymerase Chain Reaction, Polyadenylated, F13O11.25, F13O11.23, F13O11.24, T29H11.210, THALIAN-DIOL DESATURASE, Longterm Effect, CYP450 Family, Neovascularization, cytochrome P450 activity, F6G17.80, DWF3, Role Concept, vitamin A1 acid metabolic process, shelf, Ontology Projects, FLOWERING TIME CONTROL PROTEIN FCA ALPHA, Ribonucleic acids, DL3600C, 5730589K01Rik, CYP703, Alkalis, Ontology, F11C18.7, Non Polyadenylated mRNA, F11C18.9, F5G3_8, Upregulation, projection, ridge, Non-Polyadenylated mRNA, polymerase chain reaction, L isomer, beta1-tub, F5M6.19, T5J17.120, label, DL4180C, F13O11_20, T29H11.200, F5M6_19, Mouse, Clinical Finding, F13O11_24, F13O11_25, Specbeta, F13O11_23, F6A4.160, DWARF 3, Peptidomics, lamellae, tunica cornea, number, FADS7, mini-ICE, Polymerase Chain Reactions, process of organ, Gene Ontology Project, Pls2, Gene Ontology, F6A4.170, Cytochrome P-450 Families, B-spec, Gene Products, Mus musculus domesticus, T12H17_100, retinoic acid metabolism, Neovascularizations, Technique, F5A8_3, lcp1, Longterm, messenger RNA, T29A15_200, anon-EST:fe1B3, Study, F21J6.102, Enzyme, Microfilament, T8K22_12, F21J6.4, Degs, F21J6.2, Retinol, SmLim, CG5870, F13D4_120, K15C23.6, CG11650, polypeptide 25, polypeptide 26, polypeptide 23, polypeptide 24, ATR4, polypeptide 21, polypeptide 22, polypeptide 20, Messenger RNA, polypeptide 18, polypeptide 19, polypeptide 16, polypeptide 17, i168, T8K22.12, Concept, near to, F5I10.21, polypeptide 14, polypeptide 15, polypeptide 12, polypeptide 13, Poly(A)+ mRNA, polypeptide 10, polypeptide 11, chemical analysis, Long Term Effects, family 71 subfamily B, F3F19_13, THAD1, LCP1, P-450 Enzyme, F3F19.10, F5I10_21, F3F19.11, F3F19.12, F3F19.13, Grip Strength, Ontology Project, RED1, 11-cis-Retinol, phenylalanine metabolism, mRNA, ATT1, b spectrin, House Mice, polypeptide 38, Ribonucleic Acid, Understanding, Tub, signalling process, polypeptide 36, microfilament, polypeptide 37, polypeptide 34, cytochrome P450, polypeptide 35, polypeptide 32, polypeptide 33, vicinity of, polypeptide 30, polypeptide 31, polypeptide 29, csd, polypeptide 27, polypeptide 28, Polyadenylated mRNA, CYTOCHROME P450 MONOOXYGENASE 83B1, F18A5_160, DmelCG11650, Mus domesticus, BIGH3, Lymphocyte cytosolic protein 1, neutral molecular compounds, cornea of camera-type eye, Cytochrome P 450, MXI10.18, Readability, Techniques, T9E8.50, MOJ9_6, F3O9_20, Roles, Monooxygenase, G-ALPHA-h, Project, MXI10_18, betaig-h3, T9E8_50, REF2, F3O9.20, prevention and control, molecule, molecula, F13P17.35, A630040M18, AA410149, UNFERTILIZED EMBRYO SAC 9, SUPERROOT 2, Gene Expressions, YUP8H12.23, F3F19_10, F25C20_25, Polyadenylated Messenger, F25C20_24, F3F19_12, F3F19_11, Inverse Polymerase Chain Reaction, CYP81F1, F13P17.22, F25C20.25, Des1, F25C20.24, Tyr, disease management, YUP8H12_23, Long-Term Effects, MJB24_3, AT5G57250, MJB24_7, D14Ertd310e, Cytochrome P 450 Enzyme System, F6A4_110, MLD, lc64p, BETA 56D, Cytochrome P450 Superfamily, ribose nucleic acid, CRP2, mouse, ribonucleic acids, lamina, 2-Amino-3-(p-hydroxyphenyl)propionic acid, P 450 Enzyme, results, AW551867, F6A4_120, T22C12.3, Corneas, AW536232, Corneal, P-450, P450 Enzyme, CYTOCHROME P450 90A1, beta-tub, Nested Polymerase Chain Reaction, mice, F12B17_50, tTGas, L-isomer, FCAALL.331, Actin, beta56D, DmelCG9277, MICE, F12B17.40, Methodological Study, Treatments, Cytochrome p450 Families, domesticus, beta-Tub, T9E8.30, F12B17_40, T9E8_30, CYTOCHROME P450 MONOOXYGENASE 81F1, Strength, Procedures, Cytochrome P-450 Oxygenase, CABBAGE 3, KLU, electron, Inverse, 6-trimethyl-1-cyclohexen-1-yl)-2, Inverse PCR, House, Messenger, betaspec, Studies, F13D4.120, Finding, phenylalanine metabolic process, F6A4_160, study, Cytochrome P-450, betatub(56D), MIG7, F11C18.12, Swiss, Up Regulation, F6A4_170, Grips, Non-Polyadenylated RNA, Actin Filaments, L Tyrosine, lpl, SPEC8, Hand Grip, Cytochrome P 450 Enzyme, CONSTITUTIVE PHOTOMORPHOGENIC DWARF, GNAH, Long-Term Effect, F6F3.25, mig7, Spec-beta, Encyclopedias, F21J6_102, Tubulin, CYP450, F6G17.1, F6G17.6, F6G17.5, F6G17.8, Enzymes, CYP90A1, count in organism, b-Spec, Anchored, l(1)G0074, cp64, negatron, Poly(A) Tail, Non Polyadenylated RNA, Acuity, Non-Polyadenylated, F1C12.160, Cytochrome P 450 Superfamily, Visual, Laboratory Mice, F8N16.14, F8N16.15, Therapeutic, Cytochrome P-450-Dependent, approaches, Nested PCR, Treatment, F8N16_14, F8N16_15, Cytochrome P 450 Families, K8K14.3, Spec, methodology, A_IG005I10.21, Laboratory, A_IG005I10_21, growth and development, House Mouse, Long Term, TG2, cdb1, unspecified, MFB13_19, SUR2, Cytochrome P 450 Oxygenase, Method, F14P1_4, TGC, CYP77A7, LC64P, Polymerase Chain, Visual Acuities, treatment, average, K24M7_14, Genomes, CG9277, MJJ3.9, ABERRANT INDUCTION OF TYPE THREE 1, l-plastin, CDB1, MFB13.19, beta-particle, prevention., Molekuel, CYTOCHROME P450 79F2, K24M7.14, P450 protein, bigh3, T1E3_20, DEGS-1, Cytochrome P450, e-, T1E3.20, Role Concepts, Microfilaments, single organism signaling, Diagnostic Findings, close to, Mdes, preventive therapy, pp65, csd2, Angiogenesis, csd3, Up-Regulation (Physiology), csd1, T1E3.4, para-Tyrosine, Procedure, Cytochrome P-450 Superfamily, Hand, DL3720W, Role, T22C12_3, Actin Microfilament, PCR, Polyadenylated Messenger RNA, CSD3, CSD2, Acid, CYP89, CSD1, protein_coding_transcript, Caspase-14 subunit p10, Projects, Cytochrome P 450 Enzymes, CBB3, Swiss Mouse, T26C19.1, Caspase-14 subunit p19, Methodological, MFD22.6, beta(-), DTB2, Vitamin A1, cdg2, 7-dimethyl-9-(2, LUTEIN DEFICIENT 5, CYP90, Material, i6, DmelLcp1, CDG2, Cytochrome P-450 Enzyme, L-Tyrosine, beta-Tub56D, Poly(A) RNA, K9E15_12, T4C9.140, 3.4.22.-, degs, T12H17.80, Effects, Alkali, K9E15.12, e(-), Angiogeneses, All Trans Retinol, F1C12_160, PLS2, Corneal neovascularization (disorder), lamella, Filament, K16E1.5, K16E1.6, pls2, T12H17_80, DEGS, YUP8H12R.1, RED ELONGATED 1, xtgfbi, F12B17.50, P-450 Enzymes, T4C9.160, Receptor Up-Regulation, Elektron, LCP-1, beta1t, Long-Term, Aquasol A, Expressions, T4C9.150, template RNA, CP1, SUBFAMILY A, F6F3.8, blood vessel formation from pre-existing blood vessels, SmLIM, Anchored PCR, Expression, Tyrosin, laminae, beta-tubulin56D, ALTERED TRYPTOPHAN REGULATION 4, RNA, Dmbeta1, F17K2.9, F17K2.8, LUT5, big-h3, Grasp, K8K14_3, Unspecified corneal neovascularization (disorder), RNS, CYTOCHROME P450 MONOOXYGENASE 71B2, family 735, subfamily K, subfamily H, subfamily F, subfamily G, RUNT 1, T4C9.170, subfamily D, subfamily B, F3M18.13, subfamily C, tirosina, subfamily A, P450 Enzymes, CYTOCHROME P450 MONOOXYGENASE, THAD, polypeptide 30 pseudogene, INSDC_feature:mRNA, All-Trans-Retinol, vitamin A1 acid metabolism, KAO1, T3A4.4, organ process, RNT1, F1M20_23, DmelCG5870, DMLCP1, beta[[1]]-tubulin, prophylaxis, postnatal growth, beta1, CSD, Longterm Effects, beta, processes, Superfamily, T20P8.6, F18A5.160, T20P8.5, tTG, control, T18B16_200, BETA, Burn, F1M20.23, F1M20.22, F1M20_22, Gene Ontology Projects, T12C24_27, F7D19.15, determination, postnatal development, DELTA AND GAMMA, Corneal neovascularization NOS (disorder), CASP-14, REDUCED EPIDERMAL FLUORESCENCE 2, betaTub1, polypeptide 2, polypeptide 1, ENT-KAURENOIC ACID OXYDASE 1, B1t, polypeptide 8, F7D19_15, Cytoskeletons, polypeptide 7, polypeptide 9, polypeptide 4, polypeptide 3, polypeptide 6, polypeptide 5, Concepts, CYTOCHROME P450 MONOOXYGENASE 91A2, Effect, RNA Gene Products, family 703, F2P9.2, family 707, family 706, corneas, family 705, F14P1.4, family 709, MDN11_4, T9I4.17, L-PLASTIN, G[a]h, Swiss Mice, F3M18_13, family 710, MJJ3_9, free, family 715, family 714, family 712, DES1, family 718, preventive measures, 1t, T24P15_16, Methodological Studies, FCAALL.274, Reaction, papilla, FCAALL.270, Therapies, T20B5.9, T12C24.27, house mouse, T24P15.16, family 722, T9I4_17, family 721, TGase2, Therapy, SIGNS SYMPTOMS, RT-rt PCR, DESC, flanges, RNA-seq, 8-nonatetraen-1-ol, CYP, KIAA0737, L[[3]]CP1, Tyrosine, Cytochrome P-450 Enzymes, l(1)G0108, Ribonukleinsaeure, Mini-ICE, F21F23_15, T5J17_120, T20D16.18, Crp2, pentosenucleic acids, Genetic Materials, T20D16.15, F5G3.8, Genetic Material, T20D16_15, FCAALL.208, F21F23.15, T20D16_18, AA536663, Mus musculus, Gene Ontologies, Ontologies, Beta <eudicots>, growth pattern, non-developmental growth, shelves, EBMD, Filaments, K16E1_6, K16E1_5, ebmd, Grasps, Corneal neovascularization, cdgg1, Cistron, Des-1, betaTub, beta1-Tubulin, Cytochrome, protein levels, F17K2.10, F17K2.11, Gene, presence, Symptoms and Signs, LMO5, MYH9.18, Cytochrome P 450 Dependent Monooxygenase, AI181842, T18B16.200, T4C9_140, Whole Transcriptome Shotgun Sequencing, F5A8.3, MYH9_18, Mice, AI747162, T29H11.190, Genetic, LPL, Corneal Angiogenesis, Actin Microfilaments, F14M2.15, beta[[1]] tubulin, L-plastin, 68kDa, Grip, ridges, F14M2.14, F6F3_8, P450, F14M2_14, F14M2_15, CYP450 Superfamily, K15C23_6, Hand Grip Strength, 65 kDa macrophage protein, T4C9_170, FCAALL.280, P 450 Enzymes, HEL-S-37, FCAALL.277, T20P8_6, KLUH, T20P8_5, Cistrons, Cytochrome P-450-Dependent Monooxygenase, Corneal Neovascularizations, family 90, development, T3A4_4, Signs and Symptoms, family 93, family 91, F6G17.10, family 98, family 97, Mus, yeast nucleic acid, betaSpec, F1C12.160B, F1C12.160A, techniques, Polyadenylated RNA, F6G17_10, Cytoskeleton, flange, Beta-ig, F11F12_12, ribonucleic acid, T29A15.200, family 83, Poly(A)+ RNA, family 82, family 81, l(1)G0198, Reactions, Nested, Cytochrome P-450 Monooxygenase, family 87, DL3725W, family 86, T4C9_150, family 89, family 88, F6G17_20, F6G17.20, YUP8H12R_1, (all-E)-Isomer, T21P5.11, Acuities, family 72, Actin Filament, family 71, ATKAO1, RRT-PCR, T4C9_160, family 76, HEL-S-45, beta-spec, family 79, family 78, family 77, F11F12.12, F11F12.13, CP64, assay, corneal neovascularization, growth, Laboratory Mouse, Actin Cytoskeletons, T12H17.100, F11F12_13, T21P5_11sodium salt, ammonium formate, 13C-labeled, IL1BC, cadmium salt, MeCN, ion, fond, CASP-1, chronic obstructive pulmonary disease (COPD), magnesium formate, CycEI, Apaf-1, zinc salt, heavy chain disease, Long Term, Bca, 5730420M11Rik, Polypeptides, protein polypeptide chains, serial element, T22F8_160, cobalt(II) formate dihydrate, Method, ATGPR7, CH3-C#N, B1, Chronic irreversible airway obstruction, GRP8, GRP7, AGM4, Analysis, Il1bc, N-ethyl O-isopropyl thiocarbamate, Sinkiang, (R*, bca, SET, Divorced, i2pp2a., hac-1, Analyses, Radioimmunoprecipitation Analyses, Assays, Tissue, CAFL - Chronic airflow limitation, proteins, Divorces, T6G21.3, IL-1BC, AI047805, DmelCG4299, set, column, disease (COPD), sample, D1, autolysin activity, Farr, nickel salt, chronic obstructive lung disease [Ambiguous], Stars, Caspase-1 subunit p10, cobalt (+2) salt, anon-53Fa, Longterm Effect, l(2)SH0173, Procedure, Cyc E, Spectrum Analysis, not genetically inherited, DmelCG7788, CHRONIC OBSTRUCTIVE AIRWAY DIS, sodium (4:1:1) salt, BG:DS07108.3, Dm1, magnesium salt, Airflow Obstruction, l(2)05206, CG6829, dark/hac-1/dapaf-1, GLYCINE-RICH PROTEIN 8, Chronic Obstructive Airways Disease, Chronic obstructive lung disease, Mainland China, HLA-DR-associated protein II, DI-2, LY57, I-2Dm, formate, Spectrometry, cromium (+3), Methodological, beta Trypsin, I-2PP1, Speed, TAF-IBETA, F2G1.4, OBSTRUCTIVE PULMONARY DISEASE (COPD), segment - adult, Drice, bacteriolytic toxin activity, ammonium (4:1) salt, TAF-Ibeta, methyl cyanide, DRICE, lead (+2) salt, STARS, 4-Dimercapto-2, rac-Dithiothreitol, nickel formate dihydrate, cycline, lead formate, Effects, threo-1, DrIce, DrICE, Cleland's reagent, DmcyclinE, aluminum salt, CAO - Chronic airflow obstruction, CHRONIC OBSTRUCTIVE PULM DIS, precursor, Chronic obstructive pulmonary disease NOS, protein-containing complex, thomson, Chalk, and RNA binding 1, CG7826, mass-to-charge ratio, Chronic obstructive pulmonary disease finding, cdi7, PULMONARY DISEASE (COPD), cyclinE, Radioimmunoprecipitation, Radioimmunoprecipitation Assays, Ly57, Gene Products, CG7835, Cdi7, CDI7, CG42273, Technique, anatomical systems, thallium (+1) salt, Longterm, PCE-2, beta-Trypsin, rubidium salt, 2pp2a, Long-Term, methanoic acid, DmcycE, ions, CG10574, CD156, Study, 2PP2A, ATGRP7, Caspase-1 subunit p20, ATGRP8, NEC, dSET, dSet, Chronic, peptidos, Chromatographies, PTHB1, 3-butanediol, dark/dapaf-1/hac-1, 1-(14)C-labeled, chronic obstructive airways disease NOS, caspase 3, dApaf-1, Proteins, COAD, Assay, potassium formate, CE-2, copper (+2) salt, COLD - Chronic obstructive lung disease, acetonitrile, buffer, chronic, Dithiothreitol, polypeptide, APAF1, Inner Mongolia, MS, l(2)k02514, native protein, Temperatures, DmCycE, Hac-1, I-2PP2A, C18, cupric formate, chemical analysis, Long Term Effects, Dm I-2, O-(1-methylethyl) ester, (COPD), chronic airway obstruction, chronic obstructive, aluminum formate, CAL - Chronic airflow limitation, Mass Spectrum Analyses, DTL, AU020952, DTT, lithium formate, holin, l(2)k02602, Radioimmunoprecipitation Analysis, underdeveloped, ensemble, Separations, GR-RBP7, Striated muscle activator of Rho-dependent signaling, GR-RBP8, Dark/Dapaf-1/HAC1, IL-1 beta-converting enzyme, ethanenitrile, Interleukin-1 beta-converting enzyme, CD156a, Longterm Effects, ME-IV, plan specification, Gene Proteins, D-CycE, chronic obstructive lung disease (disorder), Z 200, chronic obstructive pulmonary disease, Hac-1/Dark, IPP2A2, T22F8.160, Meth, NCMe, determination, and rna binding 2, Chronic Airflow Obstructions, DmelCG6829, zinc formate, CG7788, crice, lead salt, protein, peptide, Techniques, ammonium tetraformate, peptido, Ccne, chronic obstructive airways disease NOS (disorder), Min, Apaf1, Chronic Obstructive Pulmonary Disease (COPD), protein aggregate, ARK, Effect, DmelCG42273, Mass Spectrum Analysis, COLD (chronic obstructive lung disease), peptides, NEC in ICD9CM_2006, TAF-I, E430039A18Rik, hypoplasia, min, arc, mAPC, copper, Vikane, ark, SCAN, T1, Chronic airflow limitation, IGAAD, lithium salt, Methodological Studies, DmelCG10574, GLYCINE RICH PROTEIN 7, ICE, Ice, necrosis, Lyw-57, dApaf1, glycine-rich RNA-binding protein 8, CHRONIC OBSTRUCTIVE PULMONARY DISEASE, ammonium (2:1) salt, Long-Term Effects, CHRONIC, phapii, obstructive lung disease, iCE, ice, D-Apaf-1, drice, Dmel_CG7826, StF-IT-1, Th, 4-dimercapto-2, segment, br37, Airflow Obstructions, Manchuria, Spectroscopy, pulmonary disease (COPD), SLP65, Ly-57, HCD, Ionen, sulfonyl fluoride, drIce, drICE, CHRONIC OBSTRUCTIVE, chronic obstructive pulmonary disease and allied conditions, Chronic airway disease, Dow Z-200, bacteriocin activity, NOS, nickel (+2) salt, Dmel_CG7835, COPD NOS, Crystal, CHRONIC OBSTRUCTIVE LUNG DIS, Mnb, MNB, parent ion, Chronic airway obstruction, SLP-65, ammonium salt, cold, BASH, MS/MS, P45, cobaltous formate, hac1, CG4299, AW124434, Methodological Study, dapaf-1S, Chronic Airflow Obstruction, R*)-1, apaf-1, lysin activity, dapaf-1L, l35Dd, precursor ion, COPD - Chronic obstructive pulmonary disease, Acetamide, copper salt, chronic obstructive airways disease, p45, Polypeptide, obstructive pulmonary disease (COPD), i2pp2a, chronic obstructive lung disease, COLD, Dapaf-1/HAC-1, Procedures, DISEASE (COPD), cesium salt, Gene, cycE, circadian rhythm, Spectrum Analyses, l(2)br37, PHAPII, CYCLE, Buffer, formic acid, Dark/Hac-1/dApaf1, Cold, method, Hac1, potassium salt, Dark/Hac-1/dApaf-1, Pulmonary Disease, polypeptide chain, reduced, Ms1, 14C-labeled, method used in an experiment, Tina, Mass, Studies, tiny, Separated, ethylcarbamothioic acid, Mass Spectroscopy, Pro-Mega, Cold Temperatures, Glass, CYCE, MS1, iones, DmelCG3938, MS2, CyclE, ipp2a2, dapaf-1, 3938, dapaf, dark, calcium formate, Chronic Obstructive, Farr Assay, l(2)k05007, dm-cycE, DARK, Suspension, taf-ibeta, male sterility 1, cromium (+3) salt, Long-Term Effect, dArk, Dapaf-1, 2-iodo-, sodium formate, BLNK-S, COPD, small, COAD - Chronic obstructive airways disease, DYRK1, nickel formate, 3H-labeled, protein complex, not elsewhere classified, igaad, strontium formate, apaf1, strontium salt, People's Republic of China, PULM DIS CHRONIC OBSTRUCTIVE, Peptide, Chronic obstructive pulmonary disease finding (finding), group, Dithiotreitol, natural protein, Protein, DL-threo-1, I2PP2A, Dyrk1, GLYCINE-RICH RNA-BINDING PROTEIN 7, CES2A1, Dark, CyeE, Dark/Apaf-I, ACETONITRILE, tandem MS, cyanomethane, chronic obstructive airway disease, Temperature, Mass Spectrum, Separation, PRSS, MALE STERILITY 1 PROTEIN, Dops, CC1, l(2)35Dd, Tripcellim, dApaf-1/DARK/HAC-1, sample population, chromic formate, Protein Gene Products, Interleukin-1 beta convertase, Trypure, dSET/TAF-Ibeta, 2610030F17Rik, Ion, 3.4.22.36, calcium salt, cold (chronic obstructive lung disease), Peptid, Chronic Obstructive Lung Disease, assay, AA407739, CG3938, dAPAF-1projections, Ribonucleic, para Tyrosine, Materials, LCD1, F14M4.21, DL3735W, F6G17_50, F14M4.22, MJB24.3, POLYPEPTIDE 7, FAMILY 77, MJB24.7, Corneal Neovascularization, T20B5_9, Cytochrome P 450 Monooxygenase, qRT-PCR, F4P12.1, F6G17_60, T11J7.16, T11J7.14, F3L17.70, 1, 3, 4, 6, lcd1, MOJ9.6, Non Polyadenylated, F6G17.50, T11J7_16, T11J7_14, molecules, kus, I, beta1tub, 2-amino-3-(4-hydroxyphenyl)propanoic acid, 3-(p-Hydroxyphenyl)alanine, CYP90A, F2P9_2, T, MDN11.4, procedures, DL3710C, Y, C14orf92, F6G17.60, F3L17_70, F6A4.110, e, F22H5.19, beta1Tub, F6G17_80, CYTOCHROME P450, CDGG1, F13O11.20, F6A4.120, Polyadenylated, F13O11.25, F13O11.23, F13O11.24, T29H11.210, THALIAN-DIOL DESATURASE, CYP450 Family, Neovascularization, cytochrome P450 activity, F6G17.80, DWF3, Role Concept, vitamin A1 acid metabolic process, shelf, FLOWERING TIME CONTROL PROTEIN FCA ALPHA, Ribonucleic acids, DL3600C, 5730589K01Rik, CYP703, Alkalis, F11C18.7, Non Polyadenylated mRNA, F11C18.9, F5G3_8, Upregulation, projection, ridge, Non-Polyadenylated mRNA, L isomer, beta1-tub, F5M6.19, T5J17.120, label, DL4180C, F13O11_20, T29H11.200, F5M6_19, Mouse, Clinical Finding, F13O11_24, F13O11_25, Specbeta, F13O11_23, F6A4.160, DWARF 3, Peptidomics, lamellae, tunica cornea, number, FADS7, mini-ICE, process of organ, Pls2, F6A4.170, Cytochrome P-450 Families, B-spec, Gene Products, Mus musculus domesticus, T12H17_100, retinoic acid metabolism, Neovascularizations, Technique, F5A8_3, lcp1, messenger RNA, T29A15_200, anon-EST:fe1B3, Study, F21J6.102, Enzyme, Microfilament, T8K22_12, F21J6.4, Degs, F21J6.2, Retinol, SmLim, CG5870, F13D4_120, K15C23.6, CG11650, polypeptide 25, polypeptide 26, polypeptide 23, polypeptide 24, ATR4, polypeptide 21, polypeptide 22, polypeptide 20, Messenger RNA, polypeptide 18, polypeptide 19, polypeptide 16, polypeptide 17, i168, T8K22.12, Concept, near to, F5I10.21, polypeptide 14, polypeptide 15, polypeptide 12, polypeptide 13, Poly(A)+ mRNA, polypeptide 10, polypeptide 11, chemical analysis, family 71 subfamily B, F3F19_13, THAD1, LCP1, P-450 Enzyme, F3F19.10, F5I10_21, F3F19.11, F3F19.12, F3F19.13, Grip Strength, RED1, 11-cis-Retinol, phenylalanine metabolism, mRNA, ATT1, b spectrin, House Mice, polypeptide 38, Ribonucleic Acid, Understanding, Tub, signalling process, polypeptide 36, microfilament, polypeptide 37, polypeptide 34, cytochrome P450, polypeptide 35, polypeptide 32, polypeptide 33, vicinity of, polypeptide 30, polypeptide 31, polypeptide 29, csd, polypeptide 27, polypeptide 28, Polyadenylated mRNA, CYTOCHROME P450 MONOOXYGENASE 83B1, F18A5_160, DmelCG11650, Mus domesticus, BIGH3, Lymphocyte cytosolic protein 1, neutral molecular compounds, cornea of camera-type eye, Cytochrome P 450, MXI10.18, Readability, Techniques, T9E8.50, MOJ9_6, F3O9_20, Roles, Monooxygenase, G-ALPHA-h, MXI10_18, betaig-h3, T9E8_50, REF2, F3O9.20, prevention and control, molecule, molecula, F13P17.35, A630040M18, AA410149, UNFERTILIZED EMBRYO SAC 9, SUPERROOT 2, Gene Expressions, YUP8H12.23, F3F19_10, F25C20_25, Polyadenylated Messenger, F25C20_24, F3F19_12, F3F19_11, CYP81F1, F13P17.22, F25C20.25, Des1, F25C20.24, Tyr, disease management, YUP8H12_23, MJB24_3, AT5G57250, MJB24_7, D14Ertd310e, Cytochrome P 450 Enzyme System, F6A4_110, MLD, lc64p, BETA 56D, Cytochrome P450 Superfamily, ribose nucleic acid, CRP2, mouse, ribonucleic acids, lamina, 2-Amino-3-(p-hydroxyphenyl)propionic acid, P 450 Enzyme, results, AW551867, F6A4_120, T22C12.3, Corneas, AW536232, Corneal, P-450, P450 Enzyme, CYTOCHROME P450 90A1, beta-tub, mice, F12B17_50, tTGas, L-isomer, FCAALL.331, Actin, beta56D, DmelCG9277, MICE, F12B17.40, Methodological Study, Treatments, Cytochrome p450 Families, domesticus, beta-Tub, T9E8.30, F12B17_40, T9E8_30, CYTOCHROME P450 MONOOXYGENASE 81F1, Strength, Procedures, Cytochrome P-450 Oxygenase, CABBAGE 3, KLU, electron, 6-trimethyl-1-cyclohexen-1-yl)-2, House, Messenger, betaspec, Studies, F13D4.120, Finding, phenylalanine metabolic process, F6A4_160, study, Cytochrome P-450, betatub(56D), MIG7, F11C18.12, Swiss, Up Regulation, F6A4_170, Grips, Non-Polyadenylated RNA, Actin Filaments, L Tyrosine, lpl, SPEC8, Hand Grip, Cytochrome P 450 Enzyme, CONSTITUTIVE PHOTOMORPHOGENIC DWARF, GNAH, F6F3.25, mig7, Spec-beta, F21J6_102, Tubulin, CYP450, F6G17.1, F6G17.6, F6G17.5, F6G17.8, Enzymes, CYP90A1, count in organism, b-Spec, l(1)G0074, cp64, negatron, Poly(A) Tail, Non Polyadenylated RNA, Acuity, Non-Polyadenylated, F1C12.160, Cytochrome P 450 Superfamily, Visual, Laboratory Mice, F8N16.14, F8N16.15, Therapeutic, Cytochrome P-450-Dependent, approaches, Treatment, F8N16_14, F8N16_15, Cytochrome P 450 Families, K8K14.3, Spec, methodology, A_IG005I10.21, Laboratory, A_IG005I10_21, growth and development, House Mouse, TG2, cdb1, unspecified, MFB13_19, SUR2, Cytochrome P 450 Oxygenase, Method, F14P1_4, TGC, CYP77A7, LC64P, Visual Acuities, treatment, average, K24M7_14, CG9277, MJJ3.9, ABERRANT INDUCTION OF TYPE THREE 1, l-plastin, CDB1, MFB13.19, beta-particle, prevention., Molekuel, CYTOCHROME P450 79F2, K24M7.14, P450 protein, bigh3, T1E3_20, DEGS-1, Cytochrome P450, e-, T1E3.20, Role Concepts, Microfilaments, single organism signaling, Diagnostic Findings, close to, Mdes, preventive therapy, pp65, csd2, Angiogenesis, csd3, Up-Regulation (Physiology), csd1, T1E3.4, para-Tyrosine, Procedure, Cytochrome P-450 Superfamily, Hand, DL3720W, Role, T22C12_3, Actin Microfilament, Polyadenylated Messenger RNA, CSD3, CSD2, Acid, CYP89, CSD1, protein_coding_transcript, Caspase-14 subunit p10, Cytochrome P 450 Enzymes, CBB3, Swiss Mouse, T26C19.1, Caspase-14 subunit p19, Methodological, MFD22.6, beta(-), DTB2, Vitamin A1, cdg2, 7-dimethyl-9-(2, LUTEIN DEFICIENT 5, CYP90, Material, i6, DmelLcp1, CDG2, Cytochrome P-450 Enzyme, L-Tyrosine, beta-Tub56D, Poly(A) RNA, K9E15_12, T4C9.140, 3.4.22.-, degs, T12H17.80, Alkali, K9E15.12, e(-), Angiogeneses, All Trans Retinol, F1C12_160, PLS2, Corneal neovascularization (disorder), lamella, Filament, K16E1.5, K16E1.6, pls2, T12H17_80, DEGS, YUP8H12R.1, RED ELONGATED 1, xtgfbi, F12B17.50, P-450 Enzymes, T4C9.160, Receptor Up-Regulation, Elektron, LCP-1, beta1t, Aquasol A, Expressions, T4C9.150, template RNA, CP1, SUBFAMILY A, F6F3.8, blood vessel formation from pre-existing blood vessels, SmLIM, Expression, Tyrosin, laminae, beta-tubulin56D, ALTERED TRYPTOPHAN REGULATION 4, RNA, Dmbeta1, F17K2.9, F17K2.8, LUT5, big-h3, Grasp, K8K14_3, Unspecified corneal neovascularization (disorder), RNS, CYTOCHROME P450 MONOOXYGENASE 71B2, family 735, subfamily K, subfamily H, subfamily F, subfamily G, RUNT 1, T4C9.170, subfamily D, subfamily B, F3M18.13, subfamily C, tirosina, subfamily A, P450 Enzymes, CYTOCHROME P450 MONOOXYGENASE, THAD, polypeptide 30 pseudogene, INSDC_feature:mRNA, All-Trans-Retinol, vitamin A1 acid metabolism, KAO1, T3A4.4, organ process, RNT1, F1M20_23, DmelCG5870, DMLCP1, beta[[1]]-tubulin, prophylaxis, postnatal growth, beta1, CSD, beta, processes, Superfamily, T20P8.6, F18A5.160, T20P8.5, tTG, control, T18B16_200, BETA, Burn, F1M20.23, F1M20.22, F1M20_22, T12C24_27, F7D19.15, determination, postnatal development, DELTA AND GAMMA, Corneal neovascularization NOS (disorder), CASP-14, REDUCED EPIDERMAL FLUORESCENCE 2, betaTub1, polypeptide 2, polypeptide 1, ENT-KAURENOIC ACID OXYDASE 1, B1t, polypeptide 8, F7D19_15, Cytoskeletons, polypeptide 7, polypeptide 9, polypeptide 4, polypeptide 3, polypeptide 6, polypeptide 5, Concepts, CYTOCHROME P450 MONOOXYGENASE 91A2, RNA Gene Products, family 703, F2P9.2, family 707, family 706, corneas, family 705, F14P1.4, family 709, MDN11_4, T9I4.17, L-PLASTIN, G[a]h, Swiss Mice, F3M18_13, family 710, MJJ3_9, free, family 715, family 714, family 712, DES1, family 718, preventive measures, 1t, T24P15_16, Methodological Studies, FCAALL.274, papilla, FCAALL.270, Therapies, T20B5.9, T12C24.27, house mouse, T24P15.16, family 722, T9I4_17, family 721, TGase2, Therapy, SIGNS SYMPTOMS, RT-rt PCR, DESC, flanges, RNA-seq, 8-nonatetraen-1-ol, CYP, KIAA0737, L[[3]]CP1, Tyrosine, Cytochrome P-450 Enzymes, l(1)G0108, Ribonukleinsaeure, Mini-ICE, F21F23_15, T5J17_120, T20D16.18, Crp2, pentosenucleic acids, Genetic Materials, T20D16.15, F5G3.8, Genetic Material, T20D16_15, FCAALL.208, F21F23.15, T20D16_18, AA536663, Mus musculus, Beta <eudicots>, growth pattern, non-developmental growth, shelves, EBMD, Filaments, K16E1_6, K16E1_5, ebmd, Grasps, Corneal neovascularization, cdgg1, Cistron, Des-1, betaTub, beta1-Tubulin, Cytochrome, protein levels, F17K2.10, F17K2.11, Gene, presence, Symptoms and Signs, LMO5, MYH9.18, Cytochrome P 450 Dependent Monooxygenase, AI181842, T18B16.200, T4C9_140, Whole Transcriptome Shotgun Sequencing, F5A8.3, MYH9_18, Mice, AI747162, T29H11.190, Genetic, LPL, Corneal Angiogenesis, Actin Microfilaments, F14M2.15, beta[[1]] tubulin, L-plastin, 68kDa, Grip, ridges, F14M2.14, F6F3_8, P450, F14M2_14, F14M2_15, CYP450 Superfamily, K15C23_6, Hand Grip Strength, 65 kDa macrophage protein, T4C9_170, FCAALL.280, P 450 Enzymes, HEL-S-37, FCAALL.277, T20P8_6, KLUH, T20P8_5, Cistrons, Cytochrome P-450-Dependent Monooxygenase, Corneal Neovascularizations, family 90, development, T3A4_4, Signs and Symptoms, family 93, family 91, F6G17.10, family 98, family 97, Mus, yeast nucleic acid, betaSpec, F1C12.160B, F1C12.160A, techniques, Polyadenylated RNA, F6G17_10, Cytoskeleton, flange, Beta-ig, F11F12_12, ribonucleic acid, T29A15.200, family 83, Poly(A)+ RNA, family 82, family 81, l(1)G0198, Cytochrome P-450 Monooxygenase, family 87, DL3725W, family 86, T4C9_150, family 89, family 88, F6G17_20, F6G17.20, YUP8H12R_1, (all-E)-Isomer, T21P5.11, Acuities, family 72, Actin Filament, family 71, ATKAO1, RRT-PCR, T4C9_160, family 76, HEL-S-45, beta-spec, family 79, family 78, family 77, F11F12.12, F11F12.13, CP64, assay, corneal neovascularization, growth, Laboratory Mouse, Actin Cytoskeletons, T12H17.100, F11F12_13, T21P5_11Mus musculus, Laboratory Mice., Alkalis, Corneal Angiogenesis, Peptidomics, Laboratory, Swiss, mice, Mus domesticus, Corneal Neovascularization, Angiogenesis, Alkali, mouse, Swiss Mouse, Corneal neovascularization NOS (disorder), House Mice, Swiss Mice, Unspecified corneal neovascularization (disorder), Neovascularization, House Mouse, Corneal neovascularization (disorder), domesticus, Corneal Neovascularizations, unspecified, House, Mus, Corneal, Corneal neovascularization, Burn, Mus musculus domesticus, Mouse, house mouse, corneal neovascularization, Neovascularizations, Mice, Laboratory MouseBru, IPP2A2, 2-amino-4-(methylsulfanyl)butanoic acid, Raw, L Isomer, Gene, LFQ, protein, Computer, protein-containing complex, PHAPII, 5730420M11Rik, peptide, Polypeptides, protein polypeptide chains, L-Isomer Methionine, Methionine, peptido, polypeptide chain, Gene Products, L-Methionine, Del(8)44H, Software Engineering, protein aggregate, Computer Program, Pedameth, Application, Svc, Open Source Softwares, SET, peptides, TAF-I, Software Application, M, Open, ipp2a2, Open Source Software, Computer Programs and Programming, Acetylations, 2pp2a, proteins, CG10574, Computer Software Application, DmelCG4299, IGAAD, set, 2PP2A, 2-amino-4-(methylthio)butanoic acid, Tools, DmelCG10574, taf-ibeta, dSET, dSet, peptidos, metionina, Racemethionine, Applications Software, phapii, Open Source, Computer Software, DL-Methionine, protein complex, Proteins, acetylation, igaad, 2-Amino-4-(methylthio)butyric acid, StF-IT-1, L-Isomer, Source Softwares, Peptide, Software Tools, Tool, group, Programs, polypeptide, Program, Computer Applications, Software Tool, native protein, natural protein, I-2PP2A, Computer Applications Software, Dm I-2, Protein, I2PP2A, Computer Applications Softwares, Methionin, Softwares, Hmet, Software, Data Base, Met, Software Applications, Col4a-1, HLA-DR-associated protein II, ensemble, DI-2, Protein., Source Software, I-2Dm, Engineering, CG4299, I-2PP1, Protein Gene Products, Computer Programs, Gene Proteins, dSET/TAF-Ibeta, Applications, 2610030F17Rik, Applications Softwares, TAF-IBETA, alpha-amino-gamma-methylmercaptobutyric acid, Peptid, TAF-Ibeta, Polypeptide, variable, AA407739, i2pp2a, Liquimeth, Computer Software ApplicationsfalseExploring Corneal Neovascularization: An Integrated Approach Using Transcriptomics and Proteomics in an Alkali Burn Mouse ModelPurpose Corneal neovascularization (CNV) impairs corneal transparency and visual acuity. The study aims to deepen our understanding of the molecules involved in CNV induced by alkali burns, facilitate a better grasp of CNV mechanisms, and uncover potential therapeutic targets. Methods Mice were selected for establishing CNV models via alkali burns. On days 3, 7, and 14 after the burns, corneal observations and histological investigations were conducted. An integrated analysis of RNA sequencing (RNA-seq)-based transcriptomics and label-free quantitative proteomics was performed in both normal and burned corneas. Bioinformatics approaches, encompassing GO and KEGG analysis, were applied to discern differentially expressed genes (DEGs) and crucial signaling pathways. Four potentially CNV-related genes were validated using qRT-PCR and Western blot. Results Significant CNV was observed on the seventh day. Forty-one genes were differentially expressed in neovascularized corneas, with 15 upregulated and 26 downregulated at both mRNA and protein levels. Bioinformatics analysis revealed that these DEGs participated in diverse biological processes, encompassing retinol and retinoic acid metabolism, neutrophil chemotaxis, and actin filament assembly, along with significant enrichment pathways like cytochrome P450, tyrosine, and phenylalanine metabolism. The upregulation of lymphocyte cytosolic protein 1 (LCP1) and cysteine and glycine-rich protein 2 (CSRP2) genes and the downregulation of transglutaminase 2 (TGM2) and transforming growth factor-beta-induced (TGFBI) genes were confirmed. Conclusions We analyzed gene expression differences in mouse corneas seven days after alkali burns, finding 41 genes with altered expression. The exact role of these genes in CNV is not fully understood, but exploring angiogenesis-related molecules offers potential for CNV treatment or prevention.2024-01-262023-11-29PXD047367NEWT:330879NEWT:377960NEWT:1131NEWT:35795NEWT:2042546NEWT:259447NEWT:295546NCBITaxon:2719036NEWT:1334565NEWT:625351NEWT:258594NCBITaxon:1280NEWT:112503NEWT:1129NEWT:309807NEWT:59753NEWT:89184NEWT:309800NEWT:281395NEWT:247480NEWT:1211601NEWT:876138NEWT:44271NEWT:193516NEWT:2315688NEWT:1073882NEWT:6819NEWT:475174NEWT:111205NEWT:428386NEWT:1117NEWT:498257NEWT:10036NEWT:32264NEWT:12215NEWT:1590NEWT:10034NEWT:33114NEWT:1596NEWT:661410NEWT:638632NEWT:224326NEWT:376619NCBITaxon:79857NEWT:1096976NEWT:3765NEWT:3767NEWT:1589NEWT:135622NEWT:4615NEWT:672127NEWT:35786NEWT:1580NEWT:399784NEWT:96731NEWT:656064NEWT:1582NEWT:3760NEWT:1584NEWT:36630NEWT:1585NEWT:383379NEWT:418106NCBITaxon:12721NEWT:10029NEWT:913645NEWT:2492962NEWT:641809NEWT:1392488NEWT:38815NEWT:317447NEWT:4688NEWT:111225NEWT:7719NEWT:5530NEWT:868565NEWT:135674NEWT:79329NEWT:30069NEWT:12637NEWT:59729NEWT:2164133NEWT:295105NEWT:108061NEWT:60711NEWT:224308NEWT:3347NEWT:49928NEWT:3349NEWT:160621NEWT:212790NEWT:110368NEWT:55350NEWT:1310161NEWT:77133NEWT:145481NEWT:1310165NEWT:29058NCBITaxon:79824NEWT:1912919NEWT:410658NEWT:5516NEWT:44688NEWT:44689NEWT:498211NEWT:345076NEWT:347256NEWT:5518NEWT:398007NEWT:1527468NEWT:498217NEWT:498216NEWT:11320NEWT:246196NEWT:246197NEWT:145458NEWT:1310173NEWT:44685NEWT:161934NEWT:156587NEWT:1148NEWT:5508NEWT:3329NEWT:419481NEWT:5507NEWT:260499NEWT:410661NEWT:1140NCBITaxon:2157NEWT:2066563NEWT:1143NEWT:1287689NEWT:1094343NEWT:1462472NEWT:1336795NEWT:644042NEWT:150808NEWT:1182590NEWT:3712NEWT:3711NEWT:3714NCBITaxon:37162NEWT:270643NEWT:2065263NEWT:177437NEWT:717966NEWT:10891NEWT:10418NEWT:118698NEWT:1616117NEWT:118696NEWT:34865NEWT:52283NEWT:28174NEWT:284812NEWT:8175NEWT:43330NEWT:1603293NEWT:44664NEWT:43346NEWT:3702NEWT:1245466NEWT:3704NEWT:244366NEWT:1246791NEWT:176597NEWT:118694NEWT:2850NEWT:118691NEWT:34871NEWT:33548NEWT:52299NEWT:8165NEWT:96794NEWT:3708NEWT:332648NEWT:44670NEWT:926571NEWT:536231NEWT:376219NEWT:219813NEWT:1510NEWT:460519NEWT:1515NEWT:572307NEWT:1432138NEWT:1424507NEWT:1194599NEWT:272844NEWT:1348799NEWT:33995NEWT:55784NEWT:1303443NEWT:9483NEWT:485NEWT:56636NEWT:2709072NEWT:2499525NEWT:2853422NEWT:487NEWT:1538553NEWT:1679718NEWT:480NEWT:67767NEWT:45972NEWT:46835NEWT:109757NEWT:582580NEWT:1185650NEWT:216778NEWT:294607NEWT:1502NEWT:128017NEWT:2836NEWT:376686NEWT:237610NEWT:95486EFO:0001352NEWT:119562NEWT:1883446NEWT:1233435NEWT:118223NEWT:11757NEWT:987059NEWT:109760NEWT:29031NEWT:317047NEWT:1509NEWT:491NEWT:460523NEWT:45954NEWT:235443NEWT:1579NEWT:1757312NEWT:85694NEWT:109786NEWT:108458NEWT:5936NEWT:321967NEWT:320637NEWT:1078283NEWT:3750NEWT:983964NEWT:11706NEWT:32644NEWT:527796NEWT:499175NEWT:109779NEWT:3745NEWT:1715989NCBITaxon:4751NEWT:3747NEWT:1116234NEWT:1255228NEWT:410289NEWT:191701NEWT:373153NEWT:1640278NEWT:472NEWT:940825NEWT:29459NEWT:529507NEWT:1071661NEWT:28128NEWT:470NEWT:5911NEWT:748693NCBITaxon:50557NEWT:39251NEWT:29491NEWT:101841NEWT:446NEWT:153481NEWT:2014887NEWT:33952NEWT:11723NEWT:445NEWT:153009NEWT:261756NEWT:166313NEWT:63366NEWT:63367NEWT:29488NEWT:215402NEWT:1547NEWT:1290454NEWT:3726NEWT:906914NEWT:81231006NEWT:28141NEWT:9031NEWT:27292NEWT:1050722NEWT:3728NEWT:108931NEWT:1293497NEWT:1055524NEWT:548NEWT:150475NEWT:267872NEWT:381666NEWT:172269NEWT:9534NEWT:2126348NEWT:5180NEWT:256737NEWT:9541NEWT:8694NEWT:33936NEWT:8692NEWT:542NEWT:2903NEWT:185579NEWT:872227NEWT:13076NEWT:2587410NEWT:207340NEWT:1006581NEWT:8673NEWT:33940NEWT:2126337NEWT:550NEWT:33941NEWT:554NEWT:451516NEWT:552NEWT:1325291NEWT:42410NEWT:36185NEWT:1054211NEWT:1225786NEWT:771870NEWT:51338NEWT:9995NEWT:575412NEWT:28112NEWT:49012NEWT:6493NEWT:10832NEWT:6494NEWT:6491NEWT:507601NEWT:520NEWT:64657NEWT:186441NEWT:643680NEWT:214092NCBITaxon:6157NEWT:13095NEWT:162425NEWT:104105NEWT:216257NEWT:9986NEWT:8654NEWT:8658NEWT:1268063NEWT:8657NEWT:9983NEWT:8655NEWT:5147NEWT:595495NEWT:28108NEWT:28104NEWT:407821NEWT:568703NCBITaxon:2NEWT:568708NEWT:1613NEWT:986NEWT:52641NEWT:28532NEWT:353152NEWT:298176NEWT:353153NEWT:227377NEWT:1774284NEWT:40674NEWT:1194669NEWT:51329NEWT:74426NEWT:443906NEWT:13037NEWT:519NEWT:2510939NEWT:7394NEWT:6063NEWT:1328388NEWT:105487NEWT:1548728NEWT:667127NEWT:9557NEWT:377586NEWT:300641NEWT:39655NEWT:9554NEWT:38323NEWT:475932NEWT:256318NEWT:206411NCBITaxon:6191NEWT:229533NEWT:214053NEWT:28550NEWT:80863NEWT:90675NEWT:52639NEWT:52638NEWT:57075NEWT:1666905NEWT:8697NEWT:861109NEWT:8695NEWT:884204NEWT:510516NEWT:1045775NEWT:1123869NEWT:9544NEWT:9545NEWT:979NEWT:7370NEWT:83906NEWT:99488NEWT:1134506NEWT:255470NEWT:38783NEWT:6426NEWT:33090NEWT:9935NEWT:287889NEWT:305959NEWT:1028307NEWT:13489NEWT:29829NEWT:92867NEWT:92866NCBITaxon:3055NEWT:51750NEWT:202950NEWT:441772NEWT:1293091NEWT:1867051NEWT:48106NEWT:202956NEWT:295027NCBITaxon:11320NEWT:632957NEWT:9925NCBITaxon:9606NEWT:90690NEWT:1436183NEWT:300273NEWT:4232NEWT:416348NEWT:11298NEWT:4236NEWT:7742NEWT:196627NEWT:1076878NEWT:200308NEWT:200302NEWT:870435NEWT:58370NEWT:9913NEWT:9915NEWT:105841NEWT:2666255NEWT:999810NCBITaxon:5693NEWT:28995NEWT:2144189NEWT:1392998NEWT:380394NEWT:1150621NEWT:226900NEWT:1266738NEWT:231490NEWT:244704NEWT:7725NEWT:9909NEWT:883796NEWT:9902NEWT:430615NEWT:563041NEWT:72664NEWT:36599NEWT:41949NEWT:249161NEWT:326423NEWT:452467NEWT:198822NEWT:36111NEWT:326424NEWT:1678078NEWT:749906NEWT:418985NEWT:749907NEWT:150847NEWT:2023717NEWT:29835NEWT:1229733NEWT:431947NEWT:69014NEWT:142809NEWT:1095183NEWT:302409NEWT:130821NEWT:27606NEWT:290610NEWT:1519788NEWT:59202NEWT:9975NEWT:8643NEWT:1801631NEWT:1159899NEWT:502780NEWT:860688NEWT:13443NEWT:35231NEWT:1774208NEWT:33059NEWT:8644NEWT:1125630NEWT:5141NEWT:46360NCBITaxon:3044782NEWT:202914NEWT:160235NEWT:502779NEWT:297246NEWT:103690NEWT:8639NEWT:1928434NEWT:8637NEWT:1114970NEWT:2096NEWT:285272NEWT:192222NEWT:9963NEWT:1617910NEWT:197911NEWT:197912NEWT:637379NEWT:12107NEWT:2785785NEWT:411901NEWT:1298722NEWT:8626NEWT:186801NEWT:105884NCBITaxon:9615NEWT:8621NEWT:58334NEWT:58331NEWT:6446NEWT:33038NEWT:8624NEWT:5116NEWT:6447NEWT:8623NEWT:5597NCBITaxon:3077NEWT:194439NCBITaxon:12637NEWT:38727NEWT:218496NEWT:420850NEWT:8618NEWT:70448NEWT:103695NEWT:300251NEWT:9940NEWT:13451NEWT:1247190NEWT:118702NEWT:118700NEWT:2126719NEWT:118705NEWT:6945NEWT:72859NEWT:2104NEWT:2627626NEWT:6943NEWT:157546NEWT:870726NEWT:91374NEWT:91373NEWT:1414448NEWT:27804NEWT:474186NEWT:54195NEWT:10136NEWT:321803NEWT:38942NEWT:4762NEWT:6941NEWT:307972NEWT:2102NEWT:34NEWT:38949NEWT:1299114NEWT:1590841NEWT:60876NEWT:1276473NEWT:2282334NEWT:1247NEWT:70667NEWT:869728NEWT:6938NCBITaxon:39054NEWT:1885322NEWT:1736309NEWT:4751NEWT:36774NEWT:194963NEWT:860918NEWT:77298NEWT:15819NEWT:109461NEWT:1085956NEWT:6928NEWT:1239NEWT:36745NEWT:400727NEWT:272560NEWT:272563NEWT:11009NEWT:913998NEWT:68335NEWT:3885NEWT:3888NEWT:649408NEWT:6915NEWT:101510NEWT:3880NEWT:272559NEWT:216816NEWT:153151NEWT:2681598NEWT:1220NEWT:515849NEWT:10141NEWT:95767NEWT:466585NEWT:1000589NEWT:42192NEWT:85963NEWT:29NEWT:85962NEWT:42197NEWT:6918NEWT:681196NEWT:143361NEWT:1223501NEWT:5656NEWT:1292NEWT:1295NEWT:1299NEWT:424718NEWT:316407NEWT:1794699NCBITaxon:183674NEWT:167387NEWT:84645NEWT:1123294NEWT:6978NEWT:209285NEWT:211586NEWT:747078NEWT:1282NEWT:1283NEWT:1000561NEWT:253836NEWT:2133NEWT:6973NEWT:176279NEWT:294381NEWT:197NEWT:1390363NEWT:35889NEWT:406072NEWT:1454958NEWT:351660NEWT:29176NEWT:201319NEWT:1073569NEWT:4787NEWT:751585NEWT:113549NEWT:46503NEWT:180788NEWT:159749NEWT:1270NEWT:388919NEWT:130081NEWT:4784NEWT:360106NEWT:4785NEWT:360104NEWT:10117NEWT:401614NEWT:10116NEWT:1280NEWT:83333NEWT:83334NEWT:242718NEWT:83332NEWT:161NEWT:242715NEWT:2951803NEWT:46515NEWT:563924NEWT:100226NEWT:1263NEWT:176299NEWT:1654360NEWT:1450134NEWT:54126NEWT:75058NEWT:13616NEWT:13613NEWT:2852005NEWT:296543NEWT:173NEWT:316435NEWT:42157NEWT:165179NEWT:1034304NEWT:105023NEWT:866628NEWT:535026NEWT:749200NEWT:1036967NEWT:266264NEWT:272942NEWT:272943NEWT:1882682NEWT:537209NEWT:145953NEWT:257309NEWT:33658NEWT:33657NEWT:203124NEWT:306254NEWT:230741NEWT:8296NEWT:117008NEWT:167748NEWT:1163394NEWT:2972NEWT:645463NEWT:749696NEWT:986075NEWT:320549NEWT:990119NEWT:77216NEWT:1111708NEWT:11855NEWT:998086NEWT:228410NEWT:493760NEWT:93163NEWT:257313NEWT:3827NEWT:400772NEWT:257310NEWT:128161NEWT:930945NEWT:332521NEWT:106350NEWT:1966486NEWT:455045NEWT:29170NEWT:269796NEWT:54571NEWT:412754NEWT:9598NEWT:52389NEWT:2665964NEWT:1423772NEWT:51056NEWT:35815NEWT:53232NEWT:1235987NEWT:257329NEWT:632138NCBITaxon:2509511NEWT:1639NEWT:188229NEWT:3818NEWT:432359NCBITaxon:37296NEWT:9103NEWT:715877NEWT:862238NEWT:29159NEWT:1155748NEWT:9593NEWT:8260NEWT:9595NEWT:2665958NEWT:246200NEWT:6087NEWT:145943NEWT:595536NEWT:1134822NEWT:240906NEWT:89920NEWT:3809NEWT:29158NEWT:44744NEWT:3879NEWT:1328881NEWT:411483NEWT:76336NEWT:3870NEWT:479437NEWT:884019NEWT:411490NEWT:169963NEWT:587NEWT:588NEWT:585NCBITaxon:43925NEWT:746128NEWT:212035NCBITaxon:1653394NEWT:1205NEWT:214693NEWT:1207NEWT:45609NEWT:239935NEWT:1680NEWT:280148NEWT:9172NEWT:2770979NEWT:112NEWT:423477NEWT:1277351NEWT:1594786NEWT:40366NEWT:3854NEWT:214687NEWT:1080228NEWT:411469NEWT:1679NEWT:333849NEWT:214684NEWT:1758543NEWT:569NEWT:411464NEWT:525283NEWT:411460NEWT:1328426NEWT:562NEWT:411470NEWT:10515NEWT:2094720NCBITaxon:2697049NEWT:294750NEWT:1663NEWT:214675NEWT:62141NEWT:65651NEWT:3848NEWT:3847NEWT:198466NEWT:327159NEWT:1045010NEWT:178876NEWT:1660NEWT:327160NEWT:573NEWT:1131757NEWT:571NEWT:142479NEWT:29595NEWT:241368NEWT:42528NEWT:1969471NEWT:9657NEWT:150596NEWT:30540NEWT:264483NEWT:439733NEWT:76777NEWT:30545NEWT:76773NEWT:1121114NEWT:663NEWT:1081927NEWT:1238993NEWT:67825NEWT:187878NEWT:1504802NEWT:1821314NEWT:103351NEWT:40354NEWT:1249668NEWT:426430NEWT:38033NEWT:37181NEWT:929439NEWT:9646NEWT:5286NEWT:7469NEWT:9643NEWT:9644NEWT:1580596NEWT:426428NEWT:63459NCBITaxon:446NEWT:2652157NEWT:2652158NEWT:40353NEWT:1276815NEWT:40324NEWT:588858NEWT:9638NEWT:9639NCBITaxon:11071NEWT:693977NEWT:242231NEWT:197221NEWT:528354NEWT:51453NEWT:1279085NEWT:28231NEWT:7460NEWT:504457NEWT:392227NEWT:1920175NEWT:1004024NEWT:103372NEWT:862751NEWT:470150NEWT:9627NEWT:1009714NEWT:73239NEWT:38018NEWT:226186NEWT:381518NEWT:659NEWT:30532NEWT:8782NEWT:30538NEWT:115357NEWT:5270NEWT:63436NEWT:28229NEWT:63433NEWT:13164NEWT:1601067NEWT:129554NEWT:40302NEWT:1249615NEWT:343232NEWT:343237NEWT:2664179NEWT:623NEWT:217219NEWT:7038NEWT:6192NCBITaxon:1639NEWT:767468NEWT:3915NEWT:1581419NCBITaxon:3570232NEWT:405534NEWT:9689NEWT:8355NEWT:633NEWT:9685NEWT:1218948NEWT:7029NEWT:9688NEWT:6182NEWT:9694NEWT:604162NEWT:1046723NEWT:186990NEWT:8364NEWT:6185NEWT:632NEWT:6183NEWT:1423800NEWT:630NCBITaxon:11019NEWT:334747NEWT:3907NEWT:3906NEWT:27315NEWT:61235NEWT:343691NEWT:1457551NEWT:15368NEWT:76717NEWT:13180NEWT:1491466NEWT:340188NEWT:170187NEWT:1755437NEWT:1042399NEWT:9681NEWT:1718NEWT:1719NEWT:692672NEWT:2697049NEWT:568813NEWT:1109443NEWT:267566NEWT:58042NEWT:7004NEWT:9669NCBITaxon:6073NEWT:1089448NEWT:615NEWT:1329349NEWT:1089444NEWT:607699NEWT:6161NEWT:206542NEWT:27337NEWT:575584NEWT:186536NEWT:257771NEWT:185687NEWT:3039NEWT:2706014NEWT:6549NEWT:8727NEWT:8726NEWT:8725NEWT:10090NEWT:8729NEWT:8720NEWT:5693NEWT:2186NEWT:8724NEWT:8723NEWT:283166NEWT:439334NEWT:8722NEWT:5697NEWT:6544NEWT:218192NCBITaxon:10114NEWT:2190NEWT:1685931NEWT:242619NEWT:557723NEWT:557722NEWT:160791NEWT:1353008NEWT:34073NEWT:402042NEWT:373995NEWT:5689NEWT:8715NEWT:3040162NEWT:544404NEWT:287535NEWT:1547922NEWT:2173NEWT:2175NEWT:6535NEWT:1232801NEWT:5691NEWT:61674NEWT:2072580NEWT:669465NEWT:1117957NEWT:6526NEWT:8709NEWT:1064539NEWT:8707NEWT:1306274NEWT:5671NEWT:13146NEWT:6523NEWT:8700NEWT:1692259NEWT:1486917NEWT:3062780NEWT:1843183NEWT:5661NEWT:157592NEWT:3482NEWT:52714NEWT:51866NEWT:58002NEWT:13136NEWT:5660NEWT:5665NEWT:1179777NEWT:6997NEWT:5666NEWT:1746091NEWT:5664NEWT:2157NEWT:70125NEWT:146479NEWT:905079NEWT:1843192NEWT:206189NEWT:2160NEWT:295139NEWT:27779NEWT:181214NEWT:6108NEWT:1720309NEWT:9612NEWT:1286640NEWT:38865NEWT:3077NEWT:9615NEWT:6100NEWT:713604NEWT:3076NEWT:2250255NEWT:112273NEWT:13563NEWT:33178NEWT:1147787NEWT:39717NEWT:62977NEWT:2562269NEWT:1440772NEWT:10040NEWT:8759NEWT:9605NEWT:9606NEWT:27717NEWT:641501NEWT:9601NEWT:8752NEWT:34038NEWT:9604NEWT:8756NEWT:74940NEWT:13551NEWT:10041NEWT:9600NEWT:1450511NEWT:439375NEWT:1857323NEWT:890382NEWT:174934NEWT:179392NEWT:2823525NEWT:115778NEWT:1538186NEWT:82996NEWT:1659668NEWT:227086NEWT:3055NEWT:195883NEWT:1450520NEWT:1042311NEWT:1123352NEWT:741258NEWT:82525NEWT:29920NEWT:82528NEWT:235909NEWT:47311NCBITaxon:813NEWT:127785NEWT:708248NEWT:47314NEWT:104660NEWT:652611NEWT:1417983NEWT:94993NEWT:6550NEWT:10068NEWT:8732NEWT:763037NEWT:1250232NEWT:1052588NEWT:1377NEWT:3555NEWT:71647NEWT:260201NEWT:35554NCBITaxon:12939NEWT:935692NEWT:1322343NEWT:32046NEWT:2222NEWT:59523NEWT:544496NEWT:59529NEWT:32049NEWT:1392696NEWT:762376NEWT:45351NEWT:445974NEWT:43179NEWT:180454NEWT:3544NEWT:5722NEWT:7901NEWT:32051NEWT:10245NEWT:55153NEWT:2944139NEWT:10243NEWT:351581NEWT:43186NEWT:70779NEWT:428146NEWT:889247NEWT:498019NEWT:1351NEWT:1438992NEWT:1352NEWT:32025NEWT:2649997NEWT:1147161NEWT:1645733NEWT:43150NEWT:69781NEWT:85831NEWT:263737NEWT:1333499NEWT:5702NEWT:95648NEWT:1349NEWT:67593NEWT:866555NEWT:100787NEWT:1401257NEWT:44491NEWT:27933NEWT:556484NEWT:94328NEWT:7956NEWT:7955NEWT:7959NEWT:645159NEWT:2261NEWT:94323NEWT:31156NEWT:3112NEWT:8801NEWT:4442NEWT:192875NEWT:1214915NEWT:1214916NEWT:284218NEWT:169683NEWT:1316931NEWT:45796NEWT:511145NEWT:213401NEWT:931281NEWT:4432NEWT:5762NEWT:5763NEWT:118099NEWT:32019NEWT:658457NEWT:420247NEWT:35525NEWT:1424337NEWT:295358NEWT:2246NEWT:2652724NEWT:5757NEWT:68415NCBITaxon:4563NEWT:5755NEWT:44447NEWT:752555NEWT:39097NEWT:347495NEWT:5759NEWT:1736231NEWT:1392NEWT:35974NEWT:2242NEWT:1396NEWT:1324588NEWT:286NEWT:391619NEWT:470921NEWT:287NEWT:1367269NEWT:633149NEWT:1149786NEWT:10239NEWT:68895NEWT:3567NEWT:68888NEWT:4897NEWT:5744NEWT:72901NEWT:213863NEWT:1905158NEWT:55571NEWT:35500NEWT:1235816NEWT:2041044NEWT:3562NEWT:4896NEWT:5740NEWT:1262161NEWT:343904NEWT:1314781NEWT:1390NEWT:11557NEWT:294NEWT:1773NEWT:82380NEWT:63186NEWT:935293NEWT:375146NEWT:471876NEWT:1772NEWT:1090134NEWT:264NEWT:263NEWT:11988NEWT:400667NEWT:408169NEWT:36809NEWT:47946NEWT:459758NEWT:105135NEWT:1764NEWT:39087NEWT:109974NEWT:413996NEWT:243277NEWT:7067NEWT:243275NEWT:586722NEWT:243273NEWT:1986198NEWT:274NEWT:7070NCBITaxon:287NEWT:408172NEWT:59919NEWT:408170NEWT:283734NEWT:7074NEWT:1436733NEWT:42229NEWT:85431NEWT:1247411NEWT:9238NEWT:13708NEWT:333760NEWT:34607NEWT:35938NEWT:1513458NEWT:1233681NEWT:2212966NCBITaxon:40559NEWT:506599NEWT:81077NEWT:84588NEWT:1279007NEWT:85433NEWT:572545NEWT:65349NEWT:300852NEWT:564933NEWT:508771NEWT:1121405NEWT:580165NEWT:253NCBITaxon:2759NEWT:93061NEWT:93062NEWT:1284813NEWT:34613NEWT:7054NCBITaxon:4932NEWT:1748NEWT:108673NEWT:2764168NEWT:943274NEWT:1488406NEWT:644223NEWT:1263082NEWT:272623NEWT:1288389NEWT:272624NEWT:886559NEWT:55521NEWT:118499NEWT:1130798NEWT:55529NEWT:256136NEWT:476272NEWT:195051NEWT:3988NEWT:561007NEWT:649908NEWT:1001135NEWT:147828NEWT:3981NEWT:3983NEWT:203696NEWT:223283NEWT:352472NEWT:235NEWT:505235NEWT:55518NEWT:97441NEWT:1154756NEWT:1202531NCBITaxon:12066NEWT:1202532NEWT:360094NEWT:1408223NEWT:1408224NEWT:29695NEWT:41364NEWT:1311NEWT:1313NEWT:1218097NEWT:1080348NEWT:1314NEWT:39491NEWT:212142NCBITaxon:5811NEWT:3972NEWT:1499105NEWT:686NEWT:192812NEWT:408188NEWT:571256NEWT:40483NEWT:688333NEWT:1119529NEWT:1303NCBITaxon:548681NEWT:318586NCBITaxon:5820NEWT:272634NEWT:198107NEWT:1979401NEWT:9267NEWT:155892NEWT:691NEWT:637910NEWT:28384NEWT:167879NEWT:1872122NEWT:1308NEWT:7091NEWT:1034015NEWT:760568NEWT:141262NEWT:1737068NEWT:1813NEWT:4087NEWT:9778NEWT:306NEWT:505693NEWT:303NEWT:97477NEWT:7111NEWT:113287NEWT:347515NEWT:79923NEWT:435258NEWT:6269NEWT:4090NEWT:4092NEWT:4093NEWT:786NEWT:4096NEWT:208895NEWT:941442NEWT:536088NEWT:311553NEWT:1226408NEWT:43984NEWT:7108NEWT:367110NEWT:40479NEWT:43989NEWT:4076NEWT:142615NEWT:317NEWT:885319NEWT:293939NEWT:497515NEWT:885318NEWT:39488NEWT:4081NEWT:273068NEWT:1316582NEWT:227166NEWT:98334NEWT:231663NEWT:4084NEWT:63577NEWT:7574NEWT:1715256NEWT:30640NEWT:348824NEWT:929793NEWT:1507179NEWT:29204NEWT:114155NEWT:4072NEWT:1337056NEWT:4073NEWT:634955NEWT:6239NEWT:102169NEWT:208893NEWT:4054NEWT:301301NEWT:98351NEWT:1263854NEWT:118503NEWT:2059687NEWT:160488NEWT:63558NEWT:61376NEWT:207559NEWT:107401NEWT:85057NEWT:985076NEWT:1215323NCBITaxon:565995NEWT:7159NEWT:267671NEWT:72491NEWT:7160NEWT:8496NEWT:7165NEWT:1257118NEWT:1387333NEWT:8010NEWT:1315282NEWT:7162NEWT:1859NEWT:27448NEWT:2708NEWT:38111NEWT:235612NEWT:243232NEWT:243230NEWT:936053NEWT:1080772NEWT:8479NEWT:8485NEWT:119856NEWT:72000NEWT:119857NEWT:49240NEWT:161398NEWT:89426NEWT:2893330NCBITaxon:3707NEWT:391295NEWT:1170828NEWT:2049433NEWT:104395NEWT:93934NEWT:9315NEWT:6289NEWT:38568NEWT:6287NEWT:38569NEWT:727NEWT:9796NEWT:118562NEWT:725NEWT:7137NEWT:469008NEWT:9321NEWT:596153NEWT:8472NEWT:1836NCBITaxon:10298NEWT:1652998NEWT:105231NEWT:104385NEWT:74649NEWT:1037924NEWT:206672NEWT:9788NEWT:4097NEWT:9305NEWT:436113NEWT:71139NEWT:9785NEWT:6279NEWT:1195774NEWT:9793NCBITaxon:780NCBITaxon:1502NEWT:6282NEWT:27457NEWT:4006NEWT:1872635NCBITaxon:5476NEWT:113208NEWT:6669NEWT:1215360NEWT:89453NEWT:1114301NEWT:51515NEWT:13249NEWT:1566338NEWT:588596NEWT:51511NEWT:8845NEWT:7998NEWT:419610NEWT:5334NEWT:382352NEWT:413071NCBITaxon:10239NEWT:332097NCBITaxon:714NEWT:1076620NEWT:11051NEWT:89462NEWT:452680NEWT:8839NEWT:4472NEWT:2758385NEWT:171101NEWT:714NEWT:5322NEWT:34199NEWT:568996NEWT:421932NEWT:312017NEWT:576131NEWT:553470NCBITaxon:10243NEWT:284593NEWT:100392NEWT:655819NEWT:5315NEWT:11082NEWT:265872NEWT:59463NEWT:337330NEWT:2285NEWT:2287NEWT:6645NEWT:251229NEWT:981087NEWT:180066NEWT:46147NCBITaxon:6312NEWT:11072NEWT:174633NEWT:52830NEWT:1416333NEWT:35024NEWT:135461NEWT:7962NEWT:99287NEWT:1817808NEWT:145262NEWT:145263NEWT:296587NEWT:694569NEWT:9739NEWT:111069NEWT:1379791NEWT:51953NEWT:57267NEWT:3197NEWT:13686NEWT:2750454NEWT:264561NEWT:1402135NEWT:36329NEWT:62615NEWT:1555636NEWT:46124NEWT:1333550NEWT:646099NEWT:72407NEWT:352914NEWT:349741NEWT:409859NEWT:157295NEWT:1263871NEWT:509169NEWT:6210NEWT:9721NEWT:137221NEWT:565050NEWT:409860NEWT:92683NEWT:1298968NEWT:5353NEWT:1034809NEWT:452659NEWT:1193501NEWT:51930NEWT:1193502NEWT:6689NEWT:194675NEWT:298315NEWT:392547NEWT:46105NEWT:104782NEWT:10181NEWT:9704NEWT:1049056NEWT:698936NEWT:13216NEWT:1009874NEWT:4498NEWT:8855NEWT:11034NEWT:3168NEWT:10185NEWT:78168NEWT:521001NEWT:192011NEWT:340912NEWT:1813887NEWT:224911NEWT:1090946NCBITaxon:11552NEWT:267608NEWT:334249NEWT:184922NEWT:6703NEWT:1498NEWT:2NEWT:35670NEWT:511693NEWT:5855NEWT:4528NEWT:35677NEWT:136841NEWT:1493NEWT:10376NEWT:1496NEWT:3674NEWT:5851NEWT:660469NEWT:935568NEWT:1365186NEWT:1813019NEWT:45474NEWT:48500NEWT:4513NEWT:5843NEWT:110205NEWT:1117645NEWT:376741NEWT:310915NCBITaxon:10407NEWT:1000364NEWT:10360NEWT:1403536NEWT:1427524NEWT:47664NEWT:260799NEWT:317548NEWT:106198NEWT:2323NEWT:3654NEWT:237561NEWT:5833NEWT:70415NEWT:3659NEWT:59620NEWT:499229NEWT:31298NEWT:1204162NEWT:1532734NEWT:635003NEWT:82688NEWT:5823NEWT:5821NEWT:44139NCBITaxon:4895NEWT:570417NCBITaxon:4896NEWT:675512NEWT:315393NEWT:3649NEWT:28903NEWT:325176NEWT:910263NEWT:28909NEWT:3641NEWT:79698NEWT:28901NCBITaxon:5796NEWT:137732NEWT:12993NEWT:398580NEWT:4565NEWT:1264690NEWT:515619NEWT:170721NEWT:34305NEWT:77020NEWT:10335NEWT:1908323NEWT:648794NEWT:83558NEWT:44586NEWT:626528NEWT:139927NEWT:4558NEWT:5888NEWT:431241NEWT:4550NEWT:4555NEWT:443226NEWT:144036NEWT:144030NEWT:288705NEWT:392815NEWT:3217NEWT:4547NEWT:3218NEWT:556182NEWT:374990NEWT:36941NEWT:1432059NEWT:154293NEWT:156471NEWT:3694NEWT:5875NEWT:156476NEWT:4543NEWT:210007NEWT:1857017NEWT:10359NEWT:1358430NEWT:10358NEWT:1381693NEWT:1735272NEWT:109298NEWT:317513NEWT:707678NEWT:580240NEWT:294128NEWT:11676NEWT:1917265NEWT:55210NEWT:718308NEWT:4530NEWT:5861NEWT:44577NEWT:1895NEWT:2558360NEWT:215358NEWT:64152NEWT:4924NEWT:2748NEWT:8049NEWT:33892NEWT:99931NEWT:9378NEWT:990346NEWT:100816NEWT:192952NEWT:1640346NCBITaxon:1313NEWT:29385NEWT:44544NEWT:529818NEWT:400540NEWT:382NEWT:4911NEWT:152480NEWT:129249NEWT:1888NEWT:1077286NEWT:943129NEWT:131567NEWT:1221594NEWT:10760NEWT:1524260NEWT:227321NEWT:192944NEWT:492670NEWT:281677NEWT:106590NEWT:260710NEWT:4918NEWT:1162296NEWT:106592NEWT:596645NEWT:46704NEWT:42345NEWT:482428NEWT:1187947NEWT:4903NEWT:10312NCBITaxon:1773NEWT:323848NEWT:190304NEWT:1432499NEWT:8030NEWT:246432NEWT:246437NEWT:36909NEWT:4909NEWT:443256NEWT:1279365NEWT:759272NEWT:1182263NEWT:943146NEWT:646532NEWT:2711NEWT:537457NEWT:479249NEWT:435623NEWT:33889NCBITaxon:131567NEWT:10306NEWT:12967NEWT:8022NEWT:12966NEWT:42353NEWT:593117NEWT:3633NEWT:319761NEWT:3635NEWT:5811NEWT:86662NEWT:180923NEWT:2050920NEWT:1451NEWT:198215NEWT:200298NEWT:12916NEWT:1400870NEWT:343NEWT:178606NEWT:84005NEWT:225117NEWT:34708NEWT:8090NEWT:537012NEWT:5801NEWT:43665NEWT:5802NEWT:4952NEWT:1266464NEWT:367830NEWT:1093790NEWT:178616NEWT:95145NEWT:358NEWT:375451NEWT:54788NEWT:357NEWT:74381NEWT:2010198NEWT:167539NCBITaxon:186538NEWT:457428NEWT:106178NEWT:316275NEWT:84023NEWT:589904NEWT:559292NEWT:316273NEWT:2762NEWT:1174673NEWT:28035NEWT:1313166NEWT:28034NEWT:690307NCBITaxon:138NEWT:29365NEWT:28038NEWT:1422NEWT:84030NEWT:1423NEWT:4932NEWT:1205903NEWT:3603NEWT:2756NEWT:2759NEWT:38293NEWT:1428NEWT:339NEWT:2751NEWT:330NEWT:139077NEWT:391904NEWT:12922NEWT:316277NEWT:163159NEWT:1306413NEWT:2813599NEWT:518766NEWT:2664373NEWT:190802NEWT:1213463NEWT:7234NEWT:9417NEWT:1216979NEWT:9895NEWT:7237NEWT:5059NEWT:31631NEWT:509924NEWT:28450NEWT:115104NEWT:5061NEWT:7240NEWT:8570NEWT:127569NEWT:5062NEWT:1408434NEWT:1241935NEWT:220668NEWT:9407NEWT:7227NEWT:193079NEWT:679895NEWT:9402NEWT:415540NEWT:336722NEWT:675060NEWT:416870NEWT:334542NEWT:313625NEWT:51240NEWT:27592NEWT:5052NEWT:227289NEWT:1985738NEWT:7215NEWT:196139NEWT:9874NEWT:5037NEWT:651182NEWT:2172103NCBITaxon:59201NEWT:7220NEWT:1876254NEWT:434271NEWT:1915NEWT:747679NEWT:66712NEWT:42752NEWT:746360NEWT:89764NEWT:543734NEWT:53408NEWT:49390NEWT:9870NEWT:256648NEWT:1261557NEWT:435590NEWT:1902NEWT:208526NEWT:1908NEWT:1169740NEWT:217459NEWT:216129NEWT:1245012NEWT:171250NEWT:528135NEWT:198732NEWT:1637254NCBITaxon:38727NEWT:176946NEWT:74790NEWT:254472NEWT:2829NEWT:126279NEWT:1228997NEWT:1428006NEWT:62335NEWT:366581NEWT:757417NEWT:216599NEWT:216595NEWT:40559NEWT:51208NEWT:216597NEWT:42736NEWT:1607839NEWT:194366NEWT:1283300NEWT:1218707NEWT:198726NEWT:1204551NEWT:99586NEWT:228577NEWT:2060328NEWT:48038NEWT:392021NEWT:436486NEWT:51655NEWT:1933298NEWT:260707NEWT:121845NEWT:8595NEWT:7263NEWT:280754NEWT:225058NEWT:186763NEWT:447135NEWT:185431NEWT:216591NEWT:29760NEWT:260704NEWT:703612NEWT:260705NEWT:1202347NEWT:1295743NEWT:546805NEWT:1505907NEWT:1216981NEWT:1249885NEWT:1972855NEWT:853NEWT:7244NEWT:1415167NEWT:36036NCBITaxon:662NEWT:9430NEWT:851NEWT:71251NEWT:208963NEWT:208964NEWT:181088NEWT:48498NEWT:669202NEWT:1193806NEWT:6306NEWT:1250006NEWT:4120NEWT:820NEWT:821NEWT:37334NCBITaxon:10357NEWT:2040765NCBITaxon:10358NCBITaxon:10359NEWT:1203258NEWT:49317NEWT:1899318NEWT:696811NEWT:9808NEWT:839NEWT:9803NEWT:1097670NEWT:92519NEWT:37347NEWT:943925NEWT:4111NEWT:37349NEWT:4113NEWT:837NEWT:640459NEWT:72568NEWT:8954NEWT:36015NEWT:51641NEWT:35168NEWT:81866NEWT:334147NEWT:1262469NEWT:555778NEWT:277944NEWT:48479NEWT:61435NEWT:627025NEWT:1097677NEWT:375939NEWT:712938NEWT:3258NEWT:112018NEWT:1906951NEWT:101364NEWT:52945NEWT:4100NEWT:1159556NEWT:1076NEWT:4102NEWT:1028688NEWT:4101NEWT:6763NEWT:803NEWT:29722NEWT:37319NEWT:419947NEWT:2847306NEWT:184545NEWT:468911NEWT:13373NEWT:266834NEWT:817NEWT:7604NEWT:6756NEWT:818NEWT:135588NEWT:1061NEWT:4571NEWT:29719NEWT:6754NEWT:452589NEWT:509068NEWT:2794344NEWT:4577NEWT:813NEWT:1365218NEWT:337677NEWT:2086510NEWT:1042986NEWT:1911079NEWT:69373NEWT:427577NEWT:264203NEWT:1480154NEWT:9858NEWT:9859NEWT:512623NEWT:1274414NEWT:2907833NEWT:38626NEWT:10298NEWT:10299NEWT:1087439NEWT:9852NEWT:9860NEWT:660025NEWT:61408NEWT:1355477NEWT:90371NEWT:55194NEWT:2907829NEWT:4153NEWT:11137NEWT:1320353NEWT:9844NEWT:278839NEWT:59552NEWT:35128NEWT:39966NEWT:7668NEWT:2929635NEWT:58228NEWT:915099NEWT:8996NEWT:1143193NEWT:681376NEWT:687914NEWT:1122233NEWT:277988NEWT:1199150NEWT:859313NEWT:59540NEWT:52904NEWT:9837NEWT:9838NEWT:9839NEWT:546414NEWT:11167NEWT:9835NEWT:7650NEWT:4146NEWT:5478NEWT:6326NEWT:7656NEWT:5476NEWT:5477NEWT:1882945NEWT:746707NEWT:299767NEWT:28835NEWT:1206781NEWT:5480NEWT:1274432NEWT:222863NEWT:2053667NEWT:859321NEWT:1274426NEWT:105751NEWT:9825NEWT:1274423NEWT:393765NEWT:104421NEWT:39946NEWT:9823NEWT:95602NEWT:6313NEWT:314539NEWT:39947NEWT:718274NEWT:1274420NEWT:859314NEWT:578458NEWT:6052038190126